FDA Nod for Liver Cancer Pill

The American FDA has approved of the use of Nexavar (sorafenib), manufactured by Bayer HealthCare AG and Onyx Pharmaceuticals Inc, as a liver cancer drug. This puts it way ahead of any competitors.
Posted : Tue, 20 Nov 2007 12:10:03 GMT
By : Brian Holmes
Category : Health
News Alerts by Email ( click here )
Health News | Home
The American FDA has approved of the use of Nexavar (sorafenib), manufactured by Bayer HealthCare AG and Onyx Pharmaceuticals Inc, as a liver cancer drug. This puts it way ahead of any competitors.

Nexavar had already been approved of in 2005dfor the treatment o f kidney cancer in over 60 countries, including the USA. Now it will be the first to be also used for liver cancer or HCC that cannot be surgically removed.

Liver cancer or HCC can be difficult to remove completely with surgery. Then, when all of the cancer is not removed, the disease proves fatal in about three to six months.

Every year, about 600,000 people die from the sixth most common form of cancer in the world, liver cancer. Over 50%of these fatalities occur in China where additional trials are being carried out of the drug. It is also is being further tested in Japan.

European regulators approved of the use of Nexavar against liver cancer in October, 2007.
Chairman of the Executive Committee, Bayer HealthCare, Arthur J. Higgins, said that the approval marked the second time in two years that “this kinase inhibitor has been granted FDA approval on a Priority Review basis, making it rapidly available to patients who previously had limited treatment options.”

He claimed that this milestone would in all likelihood “establish Nexavar as the standard systemic therapy for the treatment of liver cancer.” This, he said was “a turning point in improving treatment outcomes in patients facing the devastating impact of this disease."

Chairman/President and CEO, Onyx Pharmaceuticals, Inc., Hollings C. Renton, said this second approval for Nexavar demonstrated their “commitment to expediting this clinical development of the innovative therapy to treat today's unmet needs in cancer.”

Onyx Pharmaceuticals, based in Emeryville, California, made a report of its first quarterly profit because of off-label sales of Nexavar last month. This was a result of an Onyx' June report which claimed that in their clinical trials involving 602 patients, the efficacy of the drug in extending the life of patients had been proven. Forty four percent of the patients who had received Nexavar survived a median of 10.7 months whereas patients who were administered only a placebo survived for a median of 7.9 months.

About twenty percent of the patients on Nexavar experienced at least one side effect such as weight loss, hair loss, fatigue, nausea and abdominal pain, hand/foot skin reactions and Diarrhea. There were also increased cases of heart attack or insufficient blood supply to the heart as well as new cases high blood pressure in some of those who had taken the treatment.

But another analysis revealed that tumors progressed more slowly in the case of patients who received Nexavar compared to patients who had received only a placebo.

Nexavar is believed to target both, the tumor cell, and the tumor vasculature. Preclinical studies proved that it targets two classes of kinases known to be involved in both cell growth and blood supply (angiogenesis) – which are two vital processes for the growth of cancer.

Although the cost is extremely high, working out to $4,700 each month, the treatment consists of taking just two tablets twice a day.

Copyright, respective author or news agency

Share/Save/Bookmark

Article : FDA Nod for Liver Cancer Pill
Print this article
Email this article

Stay Updated
News gadget on your Google homepage
Subscribe to a news feed in Google Reader


Related News

Serbia extends school break to fight flu epidemic
Belgrade - Serbia has extended the autumn school break for the second time in the past week to reduce the impact of the swine flu, Education Minister Zarko Obradovic said Tuesday. The vacation has been extended by an additional six days, from this We...

Ukraine: Flu still spreading, but situation stabilizing - Summary
Kiev - The number of deaths and infections from flu was still rising in Ukraine on Monday, as government officials argued the outbreak was showing signs of stabilizing. Today we cle...

First death from swine flu in Baltic states
Riga - A 50-year-old Latvian woman on Monday became the first person in the Baltics to die of the virulent A/H1N1 flu virus, known commonly as swine flu. The unidentified woman died at the P Stradins University Hospital in the capital Riga, the Balti...

Ukraine government: Flu still spreading, but situation stabilising
Kiev - The number of deaths and infections from flu were still rising in Ukraine on Monday, as government officials argued the outbreak was showing signs of stabilizing. Today we clearly had certain positive signs of a reduction in the flu infection...

Nose spray boosts memory while you nap
Hamburg - A new nasal spray boosts short-term memory while you sleep, according to a team of German scientists at a sleep research lab. In a research report in The FASEB Journal, the researchers show that a molecule from the body's immune system (int...

Babies without dads think differently
Hamburg - The brains of babies raised without fathers may be wired differently than those of babies raised by both parents, according to findings by German scientists working with rodents. Fatherless rodent babies exhibit significantly different ne...

Seasonal flu and its symptoms
Hamburg - A seasonal influenza infection can be recognized by a classic progression through a series of symptoms typically starting with a high fever, pain in the limbs, headache and a feeling of general malaise and exhaustion. It then progresses to ...

Have your Say
Name
Email
Subject
Your Comment

Enter Verification code
 
  

 

 

More Health News click here
Follow The Earth Times
Subscribe to RSS Follow Earth Times on TwitterNews by email
Share/Save/Bookmark

 
 



 
Subscribe to free Earthtimes
News Alerts by Email Click here
For RSS Feeds Click here
or Create your own RSS

Add to Google Toolbar
Breaking News
Press Releases

 
 
Nexavar


The Earth Times
News Category

© 2009 www.earthtimes.org, The Earth Times, All Rights Reserved | Privacy Policy
Earth Times accept no responsibility or liability either directly or indirectly for views or opinions expressed in articles or comments.